Research Use Only — Not for Human Consumption. All content below is intended exclusively for qualified laboratory researchers. Nothing on this page is medical advice, and no product discussed is intended for human or veterinary use.

Introduction

CJC-1295 — widely referenced in the research literature as Modified GRF (1-29) — is a synthetic 29-amino-acid analog of growth hormone–releasing hormone (GHRH). It belongs to the broader family of GHRH analogs that have been studied since the endogenous hypothalamic peptide was first characterized in the early 1980s. For laboratory scientists, CJC-1295 is of interest primarily as a molecular tool: its modified sequence confers resistance to enzymatic degradation, making it a durable probe for studying GHRH receptor pharmacology, pituitary cell signaling, and peptide structure–activity relationships in controlled in vitro settings.

Molecular Structure and Key Modifications

Native human GHRH is a 44-amino-acid peptide, but its biological activity resides almost entirely in the N-terminal 29 residues. CJC-1295 builds on the GRF (1-29) fragment — the shortest sequence retaining full receptor activity — with four targeted substitutions that improve its behavior in laboratory preparations:

• D-Alanine at position 2 replaces the native L-alanine, conferring resistance to dipeptidyl peptidase IV (DPP-IV), the enzyme that rapidly cleaves the N-terminus of native GHRH.
• Glutamine at position 8 (replacing asparagine) enhances hydrogen bonding at the receptor interface.
• Alanine at position 15 (replacing glycine) increases the peptide’s alpha-helical content.
• Leucine at position 27 (replacing methionine) eliminates an oxidation-prone residue, improving chemical stability during storage and handling.

The resulting 29-residue sequence presents an amphipathic alpha-helix that docks into the extracellular domain of the GHRH receptor (GHRHR), a Class B G-protein-coupled receptor expressed on somatotroph cells of the anterior pituitary.

Receptor Binding and Intracellular Signaling

In receptor-binding studies, CJC-1295 acts as a selective GHRHR agonist. Engagement of the receptor activates the Gs protein cascade: adenylate cyclase produces cyclic AMP, protein kinase A is activated, and downstream signaling converges on growth hormone gene transcription and secretion machinery in somatotroph cell models. This mechanism has been mapped in detail through receptor mutagenesis and ligand-binding assays in cultured pituitary cell lines, providing a well-defined in vitro system for probing structure–activity relationships across the GHRH analog family.

Laboratories commonly pair CJC-1295 with receptor antagonists or with competitive GHRH ligands to dissect binding-site contributions, making it a versatile reference compound in comparative peptide pharmacology studies.

In Vitro Study Applications

Because it resists rapid enzymatic cleavage, CJC-1295 is well suited to extended cell-culture experiments where native GHRH would degrade within minutes. Common laboratory applications include:

1. Receptor pharmacology screens — measuring cAMP accumulation, calcium mobilization, or reporter-gene activation in GHRHR-transfected cell lines to rank ligand potency.
2. Structure–activity mapping — systematically varying residues at positions 1, 2, 8, and 27 to quantify each substitution’s contribution to binding affinity and helix stability.
3. Analytical method development — serving as a reference standard for RP-HPLC, mass spectrometry, and circular dichroism studies of helical peptide conformation.
4. Stability and formulation research — assessing degradation pathways (oxidation, deamidation, isomerization) in lyophilized and solution-phase peptide preparations.

Analytical Characterization

Every CJC-1295 research sample should be verified by orthogonal analytical methods before use in cell-based assays. High-performance liquid chromatography confirms purity and identity against the expected retention profile; electrospray mass spectrometry verifies the monoisotopic mass of the 29-residue sequence; and circular dichroism spectroscopy can confirm the alpha-helical secondary structure that the position-15 alanine substitution is designed to promote. Certificates of Analysis documenting these parameters are standard practice in professional peptide research supply chains.

Literature Context

The pharmacological foundation for CJC-1295 was established in early characterization work demonstrating that tetra-substituted GRF (1-29) analogs produce prolonged GHRH-receptor stimulation compared with native-sequence fragments (Teichman et al., Journal of Clinical Endocrinology & Metabolism, 2006). The molecular cloning and functional characterization of the human GHRH receptor provided the receptor-level framework for all subsequent analog work (Gaylinn et al., Molecular Endocrinology, 1993).

Conclusion

CJC-1295 (Modified GRF 1-29) occupies a distinct niche in peptide research: a degradation-resistant, well-characterized GHRH analog whose four substitutions each address a specific stability or binding challenge. For laboratories running receptor pharmacology screens, structure–activity studies, or analytical method development, it offers a durable and mechanistically transparent probe — provided every experiment is framed strictly as laboratory research and every sample is analytically verified before use.

Research Use Only — Not for Human Consumption. This material is for qualified laboratory researchers and describes laboratory applications only. It contains no medical, therapeutic, dosing, or reconstitution guidance, and no product described here is intended for human or veterinary use.